3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Completed
6
Not yet recruiting
2
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Thromboprophylaxis
1
Pulmonary Embolism
1
Neoplasms
1
Interventions
Paclitaxel
24
Oxaliplatin
24
Capecitabine
24
Gemcitabine
21
Cisplatin
21
Fluorouracil
20
Drug Therapy
18
Docetaxel
18
Carboplatin
17
pembrolizumab
15
Leucovorin
15
Irinotecan
15
Radiotherapy
12
tislelizumab
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Specimen Handling
9
Pemetrexed
9
Radiation
8
Injections
8
Cetuximab
8
toripalimab
7
Surgical Procedures, Operative
7
Radiotherapy, Intensity-Modulated
7
Azacitidine
7
venetoclax
6
sintilimab
6
Trastuzumab
6
Topotecan
6
Standard of Care
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Not yet recruiting
×
apixaban
×
Clear all
NCT07493304
2026-03-25
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3
Not yet recruiting
1,600 enrolled
NCT07160686
2025-09-08
THROMBO-STOP
University of Birmingham
Phase 3
Not yet recruiting
1,456 enrolled